Industry veteran Dennis Steadman elected chairman and member of the Piedmont Pharmaceuticals Board of Directors
Greensboro, N.C. (PRWEB) July 15, 2014
Piedmont Pharmaceuticals, LLC, an innovative specialty pharmaceutical company focused on animal health and human therapeutics, today announced its Board of Directors and shareholders have elected industry veteran Dennis Steadman chairman and member of the Board of Directors effective immediately.
“There is no better person than Dennis Steadman to help Piedmont Pharmaceuticals as we transition the company to a fully integrated research and development, marketing and sales pet health business,” said Roland Johnson, founder, CEO and member of the Board of Directors of Piedmont Pharmaceuticals, LLC. “His strategic vision, combined with operational experience ranging from capital funding and product development, to building and leading commercial organizations is exactly what Piedmont Pharmaceuticals needs as the company enters its next phase of growth.”
Steadman, an experienced animal health executive was the founder and CEO of Velcera, Inc., a pet health company acquired in 2013 by Perrigo Company. Prior to Velcera, he held executive and consulting positions for more than 35 years, including Vice President, North American Operations and Global Management Committee Member with Merial Ltd., a leading global animal health company, multiple domestic, international and global executive positions with Merck animal health, and more than a decade with a consulting subsidiary of Chase Manhattan Bank. Steadman holds a master’s degree in Agricultural Economics and a bachelor’s degree in Business Management from Pennsylvania State University and has completed the Executive Program in Finance at the Harvard Business School.
“Piedmont has one of the largest and most impressive pet prescription product portfolios in the industry today including the first of its kind soft chew pet drug delivery platform,” said Dennis Steadman. “Piedmont has now built itself to the brink of breakthrough value and material industry impact and I look forward to helping accelerate the company’s success.”
About Soft Chew Formulation
In 2013, the US Food and Drug Administration’s Center for Veterinary Medicine approved Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. The flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category. The soft chew formulation provides pet owners with a convenient and friendly way to medicate dogs.
About Piedmont Pharmaceuticals, LLC
Piedmont Pharmaceuticals, LLC, is a strategic development and licensing company focused on animal health and human therapeutics with specific expertise in parasitology and drug delivery systems. For more information visit http://www.piedmontpharma.com.